ClinicalTrials.Veeva

Menu

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

InSightec logo

InSightec

Status

Enrolling

Conditions

Neurology
Movement Disorders
Parkinsons Disease

Treatments

Device: Exablate Pallidotomy, Unilateral

Study type

Observational

Funder types

Industry

Identifiers

NCT05539196
PD006PAS/PD015

Details and patient eligibility

About

This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.

Full description

This is a post-approval registry which is required by of the approval under PMA P150038/S014 for the Exablate® Model 4000 (Exablate Neuro) Type 1.0 and Type 1.1 for unilateral pallidotomy in the treatment of idiopathic Parkinson's Disease with medication-refractory moderate to severe motor complications. Subjects participating in this registry will have received a unilateral pallidotomy using the commercially available Exablate Neuro.

The following assessments will be collected at Baseline, 3, 6, and 12 months post Exablate procedure and annually thereafter for 5 years:

Adverse Events (AEs) (does not apply to Baseline Visit) Medication usage MDS-UPDRS Unified Dyskinesia Rating Scale EQ-5D-5L WPAI-GH Clinician and Patient Global Impression of Change Patient Satisfaction Questionnaire

Enrollment

60 estimated patients

Sex

All

Ages

30 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women, age 30 years and older.
  • Subject undergoing a planned an Exablate procedure for their Parkinson's Disease with Motor Complications per local institution standard of care.
  • Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all Registry visits.
  • Subject has signed and received a copy of the approved informed consent form.

Exclusion criteria

  • Subject does not agree to participate or is unlikely to participate for the entirety of the Registry.

Trial design

60 participants in 1 patient group

Post Exablate Neuro Pallidotomy for Parkinson's Disease with Motor Complications
Description:
The population enrolled in this registry will be comprised of male and female patients that plan to be treated using the Exablate Neuro system for advanced, idiopathic Parkinson's disease with medication-refractory moderate to severe motor complications. No intervention is performed under this registry protocol.
Treatment:
Device: Exablate Pallidotomy, Unilateral

Trial contacts and locations

5

Loading...

Central trial contact

Kingsley Nwaogu; Julia Zhu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems